cas 1953-04-4|| where to buy Galantamine hydrobromide

Nom du produit:Galantamine hydrobromide

IUPAC Name:(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol hydrobromide

Unité d'emballage	Stock disponible	Prix($)
CM110074-100mg	3-4 Weeks	ƅœƩ
CM110074-250mg	4-5 Weeks	ȋşş

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1953-04-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1953-04-4; Formule moléculaire:C17H22BrNO3; Point de fusion:-; Code SMILES:O(C)C1=C2C=3[C@]4([C@@](O2)(C[C@@H](O)C=C4)[H])CCN(C)CC3C=C1.Br; Densité:

: Numéro de catalogue:CM110074; Poids moléculaire:368.27; Point d'ébullition:; N° Mdl:MFCD00067672; Stockage:Store at 2-8 ℃

: ZUNVEYL; Alpha Cognition announced that the FDA has granted approval for ZUNVEYL® (benzgalantamine) previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer’s disease. ZUNVEYL, a prodrug of AD treatment galantamine and an acetylcholinesterase inhibitor (AChEI), is postulated to exert its therapeutic effect by preventing the breakdown of acetylcholine, the important brain neurotransmitter involved in memory, motivation, and attention functions. The approval of ZUNVEYL is a pivotal moment in the fight against Alzheimer’s disease as it is only the second oral AD treatment to be approved in more than a decade.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.